678 related articles for article (PubMed ID: 20569105)
1. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
Castelo-Branco C; Steinvarcel F; Osorio A; Ros C; Balasch J
Gynecol Endocrinol; 2010 Oct; 26(10):736-42. PubMed ID: 20569105
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
3. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
4. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
[TBL] [Abstract][Full Text] [Related]
6. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
[TBL] [Abstract][Full Text] [Related]
7. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome.
Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY
Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907
[TBL] [Abstract][Full Text] [Related]
9. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
Li L; Chen X; He Z; Zhao X; Huang L; Yang D
J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
[TBL] [Abstract][Full Text] [Related]
10. [Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome].
Hu WH; Qiao J; Zhao SY; Zhang XW; Li MZ
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):487-91. PubMed ID: 17068620
[TBL] [Abstract][Full Text] [Related]
11. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study.
Zhang HY; Guo CX; Zhu FF; Qu PP; Lin WJ; Xiong J
Arch Gynecol Obstet; 2013 Mar; 287(3):525-31. PubMed ID: 23108387
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
14. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
Piouka A; Farmakiotis D; Katsikis I; Macut D; Gerou S; Panidis D
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism.
Pigny P; Cortet-Rudelli C; Decanter C; Deroubaix D; Soudan B; Duhamel A; Dewailly D
Fertil Steril; 2000 May; 73(5):972-7. PubMed ID: 10785223
[TBL] [Abstract][Full Text] [Related]
16. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
19. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
20. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
